239 related articles for article (PubMed ID: 35332058)
1. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
McInnes IB; Ostor AJK; Mease PJ; Tillett W; Baraliakos X; de Vlam K; Bessette L; Lippe R; Maniccia A; Feng D; Gao T; Zueger P; Saffore C; Kato K; Song IH; Deodhar A
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35332058
[TBL] [Abstract][Full Text] [Related]
2. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
[TBL] [Abstract][Full Text] [Related]
4. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
5. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD
Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026
[TBL] [Abstract][Full Text] [Related]
6. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Pacheco-Tena C; Haaland D; Chen L; Duan Y; Zueger P; Liu J; Lippe R; Pangan AL; Behrens F
RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663636
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
Deodhar A; van der Heijde D; Sieper J; Van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Ostor A; Combe B; Sui Y; Chu AD; Song IH
Arthritis Rheumatol; 2022 Jan; 74(1):70-80. PubMed ID: 34196498
[TBL] [Abstract][Full Text] [Related]
10. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Mease PJ; Lertratanakul A; Anderson JK; Papp K; Van den Bosch F; Tsuji S; Dokoupilova E; Keiserman M; Wang X; Zhong S; McCaskill RM; Zueger P; Pangan AL; Tillett W
Ann Rheum Dis; 2021 Mar; 80(3):312-320. PubMed ID: 33272960
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
[TBL] [Abstract][Full Text] [Related]
12. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
McInnes IB; Anderson JK; Magrey M; Merola JF; Liu Y; Kishimoto M; Jeka S; Pacheco-Tena C; Wang X; Chen L; Zueger P; Liu J; Pangan AL; Behrens F
N Engl J Med; 2021 Apr; 384(13):1227-1239. PubMed ID: 33789011
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
Burmester GR; Cohen SB; Winthrop KL; Nash P; Irvine AD; Deodhar A; Mysler E; Tanaka Y; Liu J; Lacerda AP; Palac H; Shaw T; Mease PJ; Guttman-Yassky E
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36754548
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
[TBL] [Abstract][Full Text] [Related]
15. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
Mease P; Kavanaugh A; Gladman D; FitzGerald O; Soriano ER; Nash P; Feng D; Lertratanakul A; Douglas K; Lippe R; Gossec L
Rheumatol Ther; 2022 Aug; 9(4):1181-1191. PubMed ID: 35606663
[TBL] [Abstract][Full Text] [Related]
16. Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Mease P; Setty A; Papp K; Van den Bosch F; Tsuji S; Keiserman M; Carter K; Li Y; McCaskill R; McDearmon-Blondell E; Wung P; Tillett W
Clin Exp Rheumatol; 2023 Nov; 41(11):2286-2297. PubMed ID: 37404160
[TBL] [Abstract][Full Text] [Related]
17. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
19. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
Strand V; Van den Bosch F; Ranza R; Leung YY; Drescher E; Zueger P; Saffore CD; Lertratanakul A; Lippe R; Nash P
Rheumatol Ther; 2021 Dec; 8(4):1827-1844. PubMed ID: 34661885
[TBL] [Abstract][Full Text] [Related]
20. Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.
van der Heijde D; Deodhar A; Maksymowych WP; Sieper J; Van den Bosch F; Kim TH; Kishimoto M; Östör AJ; Combe B; Sui Y; Duan Y; Wung PK; Song IH
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
